Cantargia has announced that the United States Patent and Trademark Office (USPTO) has granted a new patent covering its antibody, nadunolimab.

The patent, which is valid until 2035 (excluding any patent term extension), protects the use of Nadunolimab in combination with chemotherapy and/or immunotherapy for the treatment of cancer.

Nadunolimab, a novel anti-IL1RAP antibody wholly owned by Cantargia, is currently in clinical development for the treatment of solid and liquid (hematological) tumours.

Cantargia's lead indication for nadunolimab is pancreatic ductal adenocarcinoma (PDAC) in combination with chemotherapy – a use that is now protected by this new patent.

In June 2025, the US FDA granted Fast Track Designation to nadunolimab for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.  

"The granted US patent is of high importance in the context of potential future commercialisation of CAN04 in this strategically important market," said Damian Marron, Interim CEO of Cantargia. 

"We continue to progress our programme in PDAC with the development of a validated diagnostic method to enable the selection of patients with high IL1RAP levels for future studies,” Marron added.

In addition to the nadunolimab patent family, Cantargia has extensive patent protection for IL1RAP-targeting antibodies and their use in therapy and diagnostics of cancer, including leukemias and solid tumours. Cantargia's patent portfolio includes over 100 patents globally, granted in key commercial territories such as the US, Europe, Japan and China.